Ozmosi | Tedisamil Drug Profile

Product Description

Mechanisms of Action: Voltage-Gated Potassium Channel Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Sweden

Approved Indications: None

Known Adverse Events: None

Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Atrial Flutter|Atrial Fibrillation

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
S219.3.118	P3	Completed	Atrial Flutter\|Atrial Fibrillation	2006-03-01	2019-03-21	Treatments
S219.3.116	P3	Completed	Atrial Fibrillation\|Atrial Flutter	2006-03-01	2019-03-21	Treatments
S219.3.117	P3	Completed	Atrial Fibrillation\|Atrial Flutter	2006-01-01	2019-03-21	Treatments
2004-000346-21	P3	Active, not recruiting	Atrial Flutter\|Atrial Fibrillation	2005-03-06	2022-03-12	Treatments

Recent News Events

Date	Type	Title
07/01/2023	PubMed	Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation.
04/11/2022	PubMed	Effect of Early Pharmacologic Cardioversion vs. Non-early Cardioversion in the Patients With Recent-Onset Atrial Fibrillation Within 4-Week Follow-Up Period: A Systematic Review and Network Meta-Analysis.
07/01/2020	PubMed	Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Tedisamil

Alternative Names: tedisamil Clinical Status: Inactive Latest Update: 2023-07-01 Latest Update Note: PubMed Publication